{"entity":{"id":"timothy-cloughesy","kind":"person","name":"Timothy F. Cloughesy","aka":[],"tldr":"Neuro-oncologist whose neoadjuvant PD-1 trial showed immunotherapy before surgery can activate immune responses in glioblastoma.","summary":"Timothy Cloughesy led the randomised pilot trial showing neoadjuvant pembrolizumab before surgery for recurrent glioblastoma enhances intratumoural T-cell responses and was associated with longer survival than adjuvant-only dosing, a template for window-of-opportunity trials in brain tumours. He co-led the vocimagene (Toca 511) and GBM AGILE platform trial efforts and directs neuro-oncology at UCLA.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cloughesy%20TF%5BAuthor%5D%20glioblastoma"}],"tags":["glioma","immunotherapy","neoadjuvant"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, UCLA Neuro-Oncology Program","institutionId":"ucla-jonsson","specialisms":["Glioblastoma","Neoadjuvant immunotherapy","Targeted therapy","Clinical trial design"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cloughesy%20TF%5BAuthor%5D%20glioblastoma"}],"papers":[{"title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","journal":"Nature Medicine","year":2019,"doi":"10.1038/s41591-018-0337-7"},{"title":"Glioblastoma: from molecular pathology to targeted treatment","journal":"Annual Review of Pathology","year":2014,"doi":"10.1146/annurev-pathol-011110-130324"}]},"route":"/people/timothy-cloughesy/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/"}],"paper":[{"id":"paper-cloughesy-toca5-glioma-jamaoncol-2020","kind":"paper","name":"Toca 5: a virus plus a prodrug in recurrent brain cancer, tested properly, and it did not work","route":"/key-papers/paper-cloughesy-toca5-glioma-jamaoncol-2020/"}],"trial":[{"id":"gbm-agile","kind":"trial","name":"GBM AGILE","route":"/trials/gbm-agile/"}]}}